Form 4: Ionis Pharma Grants Options to HR Chief Shannon Devers

Ionis Pharmaceuticals granted 19,350 non-qualified stock options to EVP, Chief Human Resources Officer Shannon L. Devers, with an exercise price of $79.67.

Summary

• Shannon L. Devers, Executive Vice President and Chief Human Resources Officer of Ionis Pharmaceuticals, Inc. (IONS), was granted 19,350 non-qualified stock options.
• The transaction date for this grant was January 2, 2026.
• Each option has an exercise price of $79.67.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The options will vest over time: 25% will vest and become exercisable on January 2, 2027, with the remaining shares vesting in 36 equal monthly installments over the subsequent three years.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Shannon L. Devers beneficially owns 19,350 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant), which is generally viewed as a neutral to slightly positive action as it aligns executive interests with shareholders, but does not provide new financial or operational performance data.

Positives

• The grant of stock options to a key executive aligns management's long-term interests with those of shareholders, incentivizing performance and retention.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity transaction.

Industry Context

The grant of stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and motivate key personnel by linking their financial incentives to the company's stock performance.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages across the biotech and pharmaceutical sectors, comparable to practices at companies like Biogen, Gilead Sciences, or Amgen, which frequently use equity incentives to align executive and shareholder interests.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of the EVP, Chief Human Resources Officer with those of shareholders, potentially leading to improved long-term company performance and value creation.
• Employees: This action reflects the company's compensation strategy for its leadership, which can influence overall employee morale and retention strategies.

Next Steps

• The granted stock options will vest according to a schedule: 25% on January 2, 2027, followed by 36 equal monthly installments over the subsequent three years.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Stock Options, Executive Compensation, Form 4, Insider Transaction, Shannon Devers, Equity Incentive Plan